GliSODin Oxidative Stress Study Presented at the 2006 International AIDS Conference 

GliSODin study on oxidative stress in immune compromised humans included in the 2006 XVI International AIDS Conference


Toronto, Canada (15 August 2006)  -, an international research community dedicated to  the Glisodin  SOD/gliadin complex, announces the inclusion of a key study on Glisodin and immune compromised individuals at the AIDS 2006 - XVI International AIDS Conference, August 13-18 2006, held in Toronto.  In this study, Glisodin was shown to restore the circulating antioxidant capacities, including Superoxide Dismustase (SOD), in the Glisodin group as compared to no change in the control and placebo group.   SOD is an endogenous antioxidant produced by the body at the cellular level, providing the first line of defense against oxidative stress.


“The effects of an orally effective SOD (Glisodin) on AIDS West African patients in a randomized double-blinded clinical study,” was conducted by French and American Researchers with HIV patients in the Ivory Coast.

Acquired immunodeficiency syndrome (AIDS) is associated with oxidative stress that is responsible for the development of pro-inflammatory disorders and organ failures. In addition, usual anti-retroviral therapies induce important oxidative disorders in promoting mitochondrial swelling, and thus contribute to the development of oxidative disorders in HIV/AIDS infected patients. The cumulative pro-oxidant effects of the infectious process itself and the potential toxicity of the anti-retroviral therapies could be the origin of most of the inflammatory and toxicological disorders observed in these patients. The objectives of the study were to assess the effects of orally effective SOD/gliadin (Glisodin) on AIDS patients.


In the study, thirty-five AIDS patients were blindly divided into three groups: 1. Placebo (n=12); 2. Non-protected SOD (1000 IU/day, n = 12) as a control; and 3. SOD/Gliadin (Glisodin) product (1000 IU/per day, n = 11). The study products were to be taken once daily, orally for 21 days. Prior to the study, it was first documented that the circulating antioxidant status and the endogenous SOD levels of the study population (n=35) was significantly decreased (p  provides research links and studies establishing proof of concept in vitro and in vivo, and efficacy in 

animal and human models.  Human studies include protection of mitochondrial DNA, inhibition of isoprostanes, protection against UV radiation and sun allergy, and other therapeutic benefits of Glisodin supplementation. 


GliSODin® is available in high potency as Super GliSODin, offering 250 mg in each vegetable capsule, 60 capsules per bottle; and as GliSODin, offering 100 mg in each vegetable capsule, 90 capsules per bottle.


For more information contact:  Novus Research Int. at 480-497-5353